# FamiCordTx

Source: https://onco.cc/companies/famicordtx/  
OnCo record `famicordtx` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FamiCordTx is a Polish company developing cell and gene therapies. Its first CAR-T therapy, which re-engineers a patient's own immune cells to attack CD19 on cancer cells, is in an early trial in leukaemia and lymphoma.

## Summary

FamiCordTx S.A., based in Warsaw, develops cell and gene therapies and is part of the FamiCord capital group; the company says it has been operating since 2019 and that one project aims to create a CAR-T cancer therapy ready for immediate administration. Its registered phase 1 trial (NCT06593145) tests FCTX-CL19-1 (tarcidomgen kimleucel), an autologous anti-CD19 CAR-T product given as a single intravenous dose, in refractory and relapsed CD19-positive B-cell neoplasms including acute lymphoblastic leukaemia, mantle cell lymphoma and large B-cell lymphoma, at sites in Warsaw and Gdańsk, with a start date of May 2023. Its first registered cancer trial, NCT06593145, was posted on ClinicalTrials.gov in September 2024.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: FamiCordTx S.A.
- HQ: Warsaw
- Type: cell-therapy
- Website: https://famicordtx.com/

## Notes

- Founding year not stated; the website says only that FamiCordTx has been operating since 2019.
- The website does not name FCTX-CL19-1; product details come from the ClinicalTrials.gov record read on 29 October 2026, whose status was 'unknown'.
- No financing figures are given on the website. Whether FamiCordTx shares are listed was not checked; stage is a best estimate.

## Sources

- Official website: https://famicordtx.com/
- ClinicalTrials.gov: phase 1 trial of FCTX-CL19-1 (NCT06593145): https://clinicaltrials.gov/study/NCT06593145

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)

---
JSON: https://onco.cc/api/v1/entities/famicordtx.json